HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate

This article was originally published in The Rose Sheet

Executive Summary

Firm will continue to step up media and commercial efforts in 2005, but intends to prioritize spending, resulting in a smaller increase compared with this year, CEO Reuben Mark says during Oct. 20 third quarter sales and earnings call. Colgate recently revised its forecast to reflect lower than expected earnings as a result of the increased spending, which has, however, contributed to market share gains and higher volume ("1The Rose Sheet" Sept. 27, 2004, p. 8). Recently launched Max Fresh toothpaste helped Colgate achieve a 37.3% market share in the toothpaste category in September, firm points out. Worldwide sales grew 6.8% to $2.7 bil., but net income fell nearly 10% to $329 mil. and diluted earnings per share dropped 7.9% to $.58. Third quarter North American sales in the oral, personal and home care divisions increased 3.8% to $623.3 mil., and operating profit grew 4.7% to $137.2 mil. Colgate also announced it will buy back 20 mil. shares of the firm's stock by the end of 2005...

You may also be interested in...



Colgate Forecast Calls For Higher Volume, Lower Profit On Spending

Colgate's effort to boost marketing support to maintain leading share positions is fueling volume sales and market share growth, but also will result in lower than expected earnings in the second half of the year, Chairman and CEO Reuben Mark warned investors during a conference call Sept. 20

Improved EU Patient Access & Reimbursement On The Cards For Translarna

Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.

Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel